NO975717L - Dehydroepiandrosteron-derivater for å forhindre progressiv vevsnekrose-reperfusjons-skade, bakteriell translokasjon og voksen respiratorisk lidelse-syndrom - Google Patents

Dehydroepiandrosteron-derivater for å forhindre progressiv vevsnekrose-reperfusjons-skade, bakteriell translokasjon og voksen respiratorisk lidelse-syndrom

Info

Publication number
NO975717L
NO975717L NO975717A NO975717A NO975717L NO 975717 L NO975717 L NO 975717L NO 975717 A NO975717 A NO 975717A NO 975717 A NO975717 A NO 975717A NO 975717 L NO975717 L NO 975717L
Authority
NO
Norway
Prior art keywords
injury
respiratory distress
distress syndrome
adult respiratory
reperfusion injury
Prior art date
Application number
NO975717A
Other languages
English (en)
Norwegian (no)
Other versions
NO975717D0 (no
Inventor
Barbara A Araneo
Urzula Orlinska
Imad S Farrukh
Raymond A Daynes
Original Assignee
Paradigm Biosciences Inc
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/480,744 external-priority patent/US5587369A/en
Priority claimed from US08/480,748 external-priority patent/US5686438A/en
Priority claimed from US08/480,745 external-priority patent/US5635496A/en
Application filed by Paradigm Biosciences Inc, Univ Utah Res Found filed Critical Paradigm Biosciences Inc
Publication of NO975717D0 publication Critical patent/NO975717D0/no
Publication of NO975717L publication Critical patent/NO975717L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO975717A 1995-06-07 1997-12-05 Dehydroepiandrosteron-derivater for å forhindre progressiv vevsnekrose-reperfusjons-skade, bakteriell translokasjon og voksen respiratorisk lidelse-syndrom NO975717L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/480,744 US5587369A (en) 1993-03-09 1995-06-07 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US08/480,748 US5686438A (en) 1993-03-09 1995-06-07 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US08/480,745 US5635496A (en) 1993-03-09 1995-06-07 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US08/516,540 US5846963A (en) 1995-06-07 1995-08-18 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
PCT/US1995/010990 WO1996040152A1 (fr) 1995-06-07 1995-09-08 Derives de deshydroepiandrosterone prevenant la necrose progressive des tissus, les lesions dues aux perfusions repetees, la translocation bacterienne et l'insuffisance respiratoire aigue des etats de choc

Publications (2)

Publication Number Publication Date
NO975717D0 NO975717D0 (no) 1997-12-05
NO975717L true NO975717L (no) 1998-02-04

Family

ID=27504245

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975717A NO975717L (no) 1995-06-07 1997-12-05 Dehydroepiandrosteron-derivater for å forhindre progressiv vevsnekrose-reperfusjons-skade, bakteriell translokasjon og voksen respiratorisk lidelse-syndrom

Country Status (8)

Country Link
US (1) US5846963A (fr)
EP (1) EP0835113A1 (fr)
JP (1) JPH11124393A (fr)
AU (1) AU699749B2 (fr)
CA (1) CA2223739A1 (fr)
FI (1) FI974346A (fr)
NO (1) NO975717L (fr)
WO (1) WO1996040152A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
ID24720A (id) * 1997-12-12 2000-08-03 Novartis Ag Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2001023405A2 (fr) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Traitement therapeutique d'affections causees par le recepteur androgene
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
JP2004537506A (ja) 2001-03-01 2004-12-16 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症を治療するためのある種のステロイドの使用
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
EP2298316A1 (fr) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Procedes de traitement therapeutique
US20040121991A1 (en) * 2002-12-20 2004-06-24 Araneo Barbara A. Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2010511611A (ja) * 2006-12-01 2010-04-15 シマ ラブス インク． 口腔経粘膜ニコチン剤形
US20090214442A1 (en) * 2006-12-01 2009-08-27 Cephalon, Inc. Oral Transmucosal Nicotine Dosage Form
WO2010107922A1 (fr) * 2009-03-17 2010-09-23 Duke University Compositions stéroïdes neuroactives et procédés d'utilisation pour réduire la teneur en cholestérol
BR112012008352A2 (pt) * 2009-09-11 2016-03-22 Bionature E A Ltd uso de compostos esteroides para distúrbios inflamatório e autoimune

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
US5175154A (en) * 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
US5001119A (en) * 1987-11-25 1991-03-19 Schwartz Arthur G 16-substituted androstanes and 16-substituted androstenes
US5110810A (en) * 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
HUT72968A (en) * 1993-03-09 1996-06-28 Univ Utah Res Found Process for producing pharmaceutical composition which is applicable for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome

Also Published As

Publication number Publication date
AU699749B2 (en) 1998-12-10
US5846963A (en) 1998-12-08
AU3541395A (en) 1996-12-30
WO1996040152A1 (fr) 1996-12-19
EP0835113A1 (fr) 1998-04-15
JPH11124393A (ja) 1999-05-11
FI974346A (fi) 1998-01-16
FI974346A0 (fi) 1997-11-26
NO975717D0 (no) 1997-12-05
CA2223739A1 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
NO975717L (no) Dehydroepiandrosteron-derivater for å forhindre progressiv vevsnekrose-reperfusjons-skade, bakteriell translokasjon og voksen respiratorisk lidelse-syndrom
WO1998055074A3 (fr) Procede de prevention de la necrose progressive de tissus, des lesions consecutives aux perfusions repetees, des translocations bacteriennes et de la detresse respiratoire chez l'adulte
Castro et al. Prevention of carbon tetrachloride-induced necrosis by inhibitors of drug metabolism—further studies on their mechanism of action
Koster et al. Intracellular and extracellular sulphydryl levels in rheumatoid arthritis.
Zgliczyński et al. Myeloperoxidase of human leukaemic leucocytes: oxidation of amino acids in the presence of hydrogen peroxide
Brown et al. Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused rat hearts.
Koike et al. Gut ischemia mediates lung injury by a xanthine oxidase-dependent neutrophil mechanism
Parks et al. Ischemic injury in the cat small intestine: role of superoxide radicals
Folch et al. Free radicals generated by xanthine oxidase mediate pancreatitis-associated organ failure
Lewis et al. Liver transplantation: intraoperative changes in coagulation factors in 100 first transplants
Meyer et al. Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency
US4923815A (en) Process for heat treating thrombin
EP1225168A3 (fr) Dérivés de prostaglandines pour le traitement du glaucome et de l'hypertension oculaire
Kehrer et al. Xanthine oxidase is not responsible for reoxygenation injury in isolated-perfused rat heart
Acan et al. Sheep brain glutathione reductase: purification and general properties
KR960705572A (ko) 안정화된 프로스타글란딘 e₁(stabilized prostaglandin e₁)
LV10195B (en) Composition for stabilizing blood plasma during pasteurization and pasteurized plasma solution for therapeutic use
IE890244L (en) Protecting tissue from reperfusion injury
EA199800701A1 (ru) БЕНЗО[С]ХИНОЛИЗИНОВЫЕ ПРОИЗВОДНЫЕ, ИХ ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5a-РЕДУКТАЗ
Janoff et al. Alpha1-proteinase inhibitor is more sensitive to inactivation by cigarette smoke than is leukocyte elastase
EP1065200A4 (fr) Derives d'aminoisoquinoleine
Espinal et al. Purification and properties of a protein activator of phosphorylated branched-chain 2-oxo acid dehydrogenase complex
US5032596A (en) Treatment of disorders associated with pulmonary hypertension and/or right heart failure
Kenney et al. A novel form of covalently bound flavin from thiamine dehydrogenase
Buchwald et al. Effect of intracoronary superoxide dismutase on regional function in stunned myocardium

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application